Serum Free Light Chain Assay as a Prognostic Marker in Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma: Impact on Survival Outcome

Background  The role of serum free light chain (FLC) as a prognostic biomarker in lymphoproliferative diseases is being increasingly studied. In this study we present the 5-year survival outcome for patients with aggressive B-cell non-Hodgkin's lymphoma (NHL) and their relation to FLC and other...

Descripción completa

Detalles Bibliográficos
Autores principales: Anoop, T.M., Narayanan, Geetha, Chacko, Steffi, Krishna, K.M. Jagathnath, Nair, Sreejith G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Pvt. Ltd. 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803539/
https://www.ncbi.nlm.nih.gov/pubmed/36588611
http://dx.doi.org/10.1055/s-0042-1743426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803539/
https://www.ncbi.nlm.nih.gov/pubmed/36588611
http://dx.doi.org/10.1055/s-0042-1743426

Ejemplares similares